CDC NEWS


powered by Surfing Waves


Latest News


Pfizer Asks F.D.A. to Authorize Its Covid-19 Vaccine for Children 5 to 11


07 Oct 2021

WASHINGTON — Pfizer and BioNTech said on Thursday morning that they had asked federal regulators to authorize emergency use of their coronavirus vaccine for children ages 5 to 11, a move that could help protect more than 28 million people in the United States.


The Latest on COVID-19 Boosters


28 Sep 2021

More than 180 million Americans, including more than 80 percent of people over age 65, are fully vaccinated against the SARS-CoV-2 virus responsible for COVID-19. There’s no question that full vaccination is the best way to protect yourself against this devastating virus and reduce your chances of developing severe or long-lasting illness if you do get sick. But, to stay ahead of this terrible virus, important questions do remain. A big one right now is: How soon will booster shots be needed and for whom?


FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations


23 Sep 2021

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in: individuals 65 years of age and older; individuals 18 through 64 years of age at high risk of severe COVID-19; and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19


The Most Common COVID-19 Booster Shot Questions, Answered


23 Sep 2021

The Food and Drug Administration has authorized Pfizer COVID-19 booster shots for people over the age of 65 and other at-risk Americans. The agency’s decision was the latest twist in the ongoing debate about when coronavirus booster shots would be necessary — and for whom.


Covid Live Updates: Extra Dose of J. & J. Vaccine Raises Protection, Company Says


21 Sep 2021

In a clinical trial, researchers found that two doses of the vaccine delivered 94 percent efficacy against mild to severe Covid-19.




Articles


COVID-19 as the Leading Cause of Death in the United States


12 Jan 2021

The current exponential increase in coronavirus dis- ease 2019 (COVID-19) is reaching a calamitous scale in the United States, potentially overwhelming the health care system and causing substantial loss of life.




Feds Authorize $22 Billion to Boost Vaccine Rollout


11 Jan 2021

The CDC will send $3 billion to the states to boost a lagging national COVID-19 vaccination program.




COVID-19 Immunity Could Last Longer Than 8 Months, Study Says


08 Jan 2021

Certain antibodies and memory cells likely last more than 8 months after someone has contracted the coronavirus, especially if they have a strong immune response to COVID-19, according to a new study published Wednesday in Science.




Pfizer Vaccine Appears to Work Against Variant, Research Shows


08 Jan 2021

Laboratory experiments indicate the Pfizer/BioNTech vaccine will offer protection against the two coronavirus variants found in the United Kingdom and South Africa.




COVID Likely the Third-Leading Cause of Death in US, CDC Says


07 Jan 2021

COVID-19 was probably the third leading cause of death in the United States during 2020, CNN reported, citing an email from statisticians with the U.S. Centers for Disease Control and Prevention.




Enroll for Free